Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

LOS ANGELES, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Today, GE HealthCare (Nasdaq: GEHC) and DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. ...

Predicting cognitive abilities from brain imaging has long been a central goal in cognitive neuroscience. While machine learning has modestly improved predictions using brain MRI data, most studies ...

A clinician, advocate, and payer provide their expert knowledge on the multiple modalities of PrEP therapy and how some can be more beneficial than others.

Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...